12/21/2023 0 Comments Pellucid marginal degeneration layer15 The application of already existing corneal stroma is another option for a substitute. 14 Nevertheless, the complicated fabrication processes for recombinant human collagen graft restrict its further application. 13 The development of three-dimensional (3D) biomaterials increasingly brings promising results for a cornea substitute that can support native keratocyte and nerve repopulation to complete corneal regeneration. 11, 12 The poor biocompatibility of keratoprosthesis causes various potential complications. The substitutes that have already been applied in clinical trials or practices include plastic-based keratoprosthesis, recombinant collagen scaffold, decellularized cornea stroma, and so on. 9, 10 The demand has promoted the development of different materials for use as cornea substitutes. 4-8Īt present, the major limitation in corneal transplantation is the global shortage of donor corneal allografts, especially in developing countries, and postoperative inflammation and graft rejection for high-risk patients further aggravate the shortage. For a series of corneal diseases with characteristics of continuous thinning of the corneal stroma located peripherally, including pellucid marginal corneal degeneration, 2, 3 advanced surgical techniques with marginal keratoplasty have been developed. 1 Corneal transplantation with donor grafts is the leading treatment that is widely accepted for irreversible corneal transparency loss. With further improvements, human-derived acellular dermis matrix could be applied in central lamellar keratoplasty and ultimately solve the shortage of donor grafts.Ĭorneal disease is one of the most important and leading causes of blindness globally, second only to cataract in overall importance. The present study demonstrated the transparency, biocompatibility, and safety of human-derived acellular dermis matrix in intrastromal keratoplasty. The thinning of the marginal corneal stroma was eliminated following the transplantation, and the curvature and corneal regularity remained stable at 6 months compared with baseline. Reepithelization was completed, and confocal microscopy revealed that keratocytes and nerves repopulated in all the grafts at 6 months postoperatively. Desirable and improved transparency of the grafts was demonstrated, and all the grafts healed without dissolution or fall at 6 months postoperatively. No abnormal ocular signs were observed at 6 months, indicating the safety of the procedure. Postoperative discomfort was relieved during the follow-up period. Photography by a slit lamp, topography by Pentacam, anterior segment-optical coherence tomography, and corneal confocal microscopy were conducted at baseline and during the follow-up period. The ocular symptoms and signs as well as graft characteristics were evaluated at baseline and at 1 day, 1 week, and 1, 3, and 6 months postoperatively. Twenty-four patients (24 eyes) with pellucid marginal corneal degeneration were enrolled, and intrastromal keratoplasty was performed with human-derived acellular dermal matrix. To investigate the transparency, biocompatibility, and safety of human-derived acellular dermal matrix for application in corneal stromal transplantation. The sponsor or funding organization had no role in the design or conduct of this research.Ĭorrespondence: Dr Xuemin Li, Department of Ophthalmology, Peking University Third Hospital, 49 North Garden Road, Haidian District, 100191, Beijing, China. This work was supported by the Beijing Municipal Science & Technology Commission, People’s Republic, and Capital Clinical Characteristic Application Research Project (No. The authors have no proprietary or financial interest in the materials used in this study and no conflicts of interest to report. All the authors participated in the revision and approval of the final version of the article. ![]() were responsible for the writing of paper. participated in performance of the research. were responsible for the research design and supervision. The registration number was ChiCTR1800016050. The trial was registered on Chinese Clinical Trial Registry. 1 Department of Ophthalmology, Peking University Third Hospital, Beijing, China.Ģ Medical Research Center, Peking University Third Hospital, Beijing, China.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |